Silo Pharma’s Nasdaq Win: A Lifeline for Its Ambitious Drug Pipeline

SARASOTA, FLA. – June 18, 2026 – Silo Pharma (Nasdaq: SILO), a developmental-stage biopharmaceutical company, has successfully navigated a period of significant uncertainty, confirming it has regained compliance with The Nasdaq Stock Market's minimum bid price requirement. The announcement closes a year-long chapter of regulatory pressure and allows the company to pivot its full attention from market survival to scientific execution. For a small-cap biotech, this is more than a procedural victory; it is a critical stabilization that underpins its entire strategy of creating long-term value through its innovative pipeline.

The Anatomy of a Compliance Battle

For any publicly traded company, maintaining a listing on a major exchange like Nasdaq is fundamental. It provides liquidity for shareholders and, crucially, access to capital markets. The exchange sets rules to ensure a baseline of financial health and investor interest, one of the most visible being Nasdaq Listing Rule 5550(a)(2), which mandates that a stock’s bid price not fall below $1.00 for 30 consecutive business days.

Silo Pharma’s journey into non-compliance began on June 27, 2025, when it received a deficiency notice from Nasdaq. Its stock had languished below the $1.00 threshold for over a month, triggering a 180-day grace period to resolve the issue. As that December deadline approached, Nasdaq granted the company a second 180-day extension, pushing the final compliance date to June 2026. This is a common but precarious path for many small-cap companies, particularly in the volatile biotech sector where timelines are long and revenue is often years away. Failure to comply ultimately leads to delisting, a move that can cripple a company by relegating its stock to the less liquid over-the-counter (OTC) markets and making it ineligible for many institutional investors.

To engineer a recovery, Silo’s management executed a 1-for-15 reverse stock split, which took effect on June 2, 2026. This corporate action consolidated every 15 shares into a single share, artificially boosting the per-share price to meet the Nasdaq minimum. While a reverse split doesn't change the company's underlying market capitalization, it is a necessary tactical maneuver to resolve the bid price deficiency. The strategy proved successful, and on June 17, Silo’s stock had traded above the $1.00 minimum for the required consecutive period, allowing Nasdaq to formally close the matter.

From Regulatory Hurdles to Renewed Focus

With the threat of delisting removed, the narrative surrounding Silo Pharma can shift decisively from regulatory mechanics to its core mission. The regain of compliance is a powerful signal of stability, reassuring investors that the company has a secure platform from which to operate and raise future capital. This is paramount for a developmental-stage firm that relies on external funding to fuel its research-intensive programs.

“We appreciate the loyalty and continuing support from our investors for our business strategies aimed at creating long-term value for stockholders,” said Eric Weisblum, Chief Executive Officer of Silo Pharma, in a statement. This sentiment underscores the importance of investor confidence, which is often eroded during periods of non-compliance. By closing this chapter, the company can now more effectively communicate its progress and potential without the shadow of a potential delisting.

The market reaction reflects this new chapter. Although the stock saw a slight dip on the day of the announcement, its price post-split remains well above the compliance threshold. More importantly, the company can now engage with the market on the merits of its science rather than the technicals of its stock listing. For a company with a market cap of just over $6 million and limited revenue, maintaining its Nasdaq listing is a lifeline that preserves its ability to attract capital and pursue its ambitious long-term goals.

A Bet on the Brain: Silo's R&D Frontier

With its market footing secured, Silo Pharma’s pipeline of novel therapeutics takes center stage. The company is focused on addressing underserved conditions in psychiatric disorders and central nervous system (CNS) diseases, a high-risk, high-reward area of medicine. Its strategy involves a blend of traditional therapeutics and cutting-edge psychedelic research, positioning it in a rapidly evolving field.

The company’s lead candidate is SPC-15, an intranasal therapeutic designed to treat post-traumatic stress disorder (PTSD) and other stress-induced anxiety disorders. Silo is actively progressing toward a first-in-human clinical trial for SPC-15, a significant milestone in any drug's development. Bolstering this program, the U.S. Patent and Trademark Office recently issued a Notice of Allowance for a key patent related to the treatment, strengthening its intellectual property position. This progress comes at a time when the FDA is showing increased openness to psychedelic-based therapies, potentially creating a favorable regulatory pathway.

Beyond PTSD, the company's portfolio includes SP-26 for fibromyalgia and chronic pain, as well as a preclinical asset targeting Alzheimer's disease—two conditions with enormous unmet medical needs. Further demonstrating its innovative edge, Silo recently filed a provisional patent for an ibogaine-based therapeutic aimed at treating traumatic brain injury (TBI). This exploration of novel psychedelic compounds highlights a commitment to pursuing breakthrough science.

Complementing its drug development is the advancement of QwikAgents, the company’s proprietary AI platform. As Weisblum noted, this is a key area of focus. The integration of artificial intelligence in drug discovery is a powerful industry trend, promising to accelerate research timelines, identify novel drug targets, and reduce the notoriously high costs of development. For a small company like Silo, leveraging AI could be a significant competitive advantage. With its Nasdaq listing secure, the long and capital-intensive journey of transforming this scientific promise into approved therapies now takes center stage for Silo Pharma.